CoreCivic (CXW)
NYSEIndustrialsReit - SpecialtySnapshot 2026-09-04
$34.71+3.12%
Close 2026-09-04 · 1-day change
NYSEIndustrialsReit - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · CXW
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within industrials on a research-validated quality screen. As of 2026-09-04.
The screen ranks CXW against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated strong grew net income 67% of the time over the next year (vs 52% for the rest of the cohort, n=6958).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive revenue growth by activating previously idle facilities and acquiring complementary businesses like Clinical Solutions Pharmacy.
Stated as a priority in 4 of last 4 quarters. Revenue increased from $488.6 million in 2025-Q1 to $684.9 million in 2026-Q2, driven by activations of multiple previously idle facilities and acquisitions including Clinical Solutions Pharmacy. ICE revenue nearly doubled in 2026-Q1 versus 2025-Q1. The trajectory is delivering consistent growth aligned with management's stated priorities.
“Financial results driven by facility activations and acquisition of CSP.”
“Strong performance driven by activation of four previously idled facilities and acquisition of CSP.”
“Strategic capital investments enabled new contract awards at four idle facilities.”
“Activations of idle facilities and acquisitions support growth.”
Improve operating income and margins through operational efficiencies and increased occupancy at activated facilities.
Stated as a priority in 4 of last 4 quarters. Operating income increased from $32.1 million in 2025-Q1 to $47.5 million in 2026-Q2. Facility operating margins improved modestly to 24.0% in 2026-Q1 from 23.6% prior year, with expectations for further margin gains as activated facilities reach stabilized occupancy. The trajectory shows progress consistent with management's focus on margin enhancement.
Grow net income and diluted earnings per share through operational improvements and share repurchases.
Stated as a priority in 4 of last 4 quarters. Net income increased from $25.1 million in 2025-Q1 to $37.1 million in 2026-Q2. Diluted EPS rose from $0.23 to $0.37 over the same period, supported by facility activations, acquisitions, and an 8.9% reduction in weighted average diluted shares outstanding. The trajectory is delivering growth consistent with management's stated goals.
“Diluted EPS of $0.37, up 5.7% year-over-year.”
Continue disciplined capital allocation through share repurchases, with expanded authorization to repurchase up to $1.2 billion in shares.
Stated as a priority in 4 of last 4 quarters. The Board expanded the share repurchase authorization from $700 million to $1.2 billion in 2026-Q2, with $755.8 million remaining available. Since program inception, 28.1 million shares have been repurchased at a cost of $444.2 million. Repurchases paused in 2026-Q2 but remain a key capital allocation tool. The trajectory shows ongoing commitment to reducing shares outstanding.
Strengthen balance sheet through asset sales, debt repayments, and credit facility amendments to support growth and capital allocation.
Stated as a priority in 3 of last 4 quarters. The company sold four facilities for $2.2 billion in 2026-Q2, using $608.5 million of net proceeds to repay debt, including $238.5 million of senior notes. The revolving credit facility was expanded from $275 million to $575 million in 2025-Q4, and an incremental $100 million term loan was obtained in 2026-Q1. The balance sheet flexibility and leverage management trajectory is delivering as planned.
Over the trailing year it converted 1.52x of net income into operating cash flow. Historically, Industrials names rated neutral grew net income 59% of the time over the next year (vs 53% for the rest of the cohort, n=6654).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Industrials names rated volatile grew net income 58% of the time over the next year (vs 57% for the rest of the cohort, n=2592).
Not investment advice. As of 2026-09-04.
“Operating margins positively impacted by activations of idled facilities.”
“Facility operating margin increased to 24.0% in 2026-Q1 from 23.6% prior year.”
“Facility operating margins decreased due to start-up expenses but expected to improve in 2026.”
“Margin improvement expected as facilities reach stabilized occupancy.”
“Diluted EPS of $0.38, up 65.2% year-over-year.”
“Diluted EPS increased 53% year-over-year to $0.26.”
“EPS growth supported by activations and acquisitions.”
“Board expanded share repurchase authorization to $1.2 billion; $755.8 million remains.”
“Repurchased 2.3 million shares for $44.7 million under repurchase program.”
“Repurchased 5.3 million shares for $97.3 million in Q4 2025.”
“Share repurchase program authorized up to $700 million aggregate.”
“Sold four facilities for $2.2 billion; repaid $608.5 million of debt.”
“Obtained $100 million incremental term loan to maintain liquidity.”
“Expanded revolving credit facility from $275 million to $575 million.”